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Abstract
Introduction Cytokeratin (CK) 14, one of several markers
expressed in normal myoepithelial/basal cells, is also expressed
in a proportion of breast carcinomas. Previous studies have
suggested that expression of such 'basal' markers predicts
different biological behaviour, with more frequent lung and brain
metastases and poorer prognosis than other carcinomas.
Methods We performed CK14 immunohistochemistry on 443
grade III invasive ductal carcinomas with extended clinical
follow-up (mean 116 months), and we correlated CK14
immunopositivity (basal-like phenotype) with clinicopathological
criteria.
Results Eighty-eight of 443 (20%) tumours showed CK14
expression. CK14-positive tumours were more likely to be
oestrogen receptor-negative (p < 0.0001) and axillary node-
negative (p = 0.001) than were CK14-negative cases. CK14-
positive cases developed less bone and liver metastases
(hazard ratio [HR] 0.49, p = 0.01, and HR 0.53, p = 0.035,
respectively) but more frequent brain metastases (HR 1.92, p =
0.051). In patients without metastatic disease, disease-free
survival in CK14-positive cases was significantly better than in
CK14-negative cases (HR 0.65, p = 0.005). In patients with
metastatic disease, however, CK14 positivity was associated
with a poorer prognosis (HR 1.84, p = 0.001). The overall
survival in CK14-positive and -negative patients was similar at 5
years (60% and 59%, respectively), but the long-term survival
was better in CK14-positive patients (HR 0.69, p = 0.02).
Conclusion These results demonstrate that basal-like tumours
differ in their biological behaviour from other tumours, with a
distinct pattern of metastatic spread. Compared to other grade
III tumours, basal-like tumours appear to have a relatively good
long-term survival but survival after metastases is poor.
Introduction
Breast cancer is a common but very diverse disease with con-
siderable survival heterogeneity [1-5]. An ongoing challenge is
to find improved methods of identifying and classifying groups
of tumours with differing biological behaviours or responsive-
ness to specific therapies. Expression profiling analysis is
reshaping our understanding of breast cancer and has pro-
vided a working model for modern breast cancer taxonomy [6-
8]. These seminal studies have systematically identified a sub-
group of breast tumours that are characterised by the expres-
sion of genes normally expressed in basal/myoepithelial cells
of normal breast, including high-molecular-weight cytokeratins
(CKs) and P-cadherin [6-10]. These findings have confirmed
and expanded the concepts first described as early as 1967
[11], and in particular those described over the last decade
[12], by conventional histopathological andPage 1 of 11
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strated that whilst most breast tumours express a purely lumi-
nal phenotype, a minority of ductal tumours (4% to 22%) will
show ultrastructural features and co-express markers that are
characteristic of the outer myoepithelial, or basal, compart-
ment of the normal breast [11-35].
Morphologically, these tumours are predominantly of high
grade [9,19,23-26,29,35] and more frequently show medul-
lary-like features [30,31] and metaplastic elements
[19,20,32,33,36-39] (Figure 1a). Immunohistochemically,
they are predominantly oestrogen receptor (ER)-, progester-
one receptor (PR)-, and C-erb B2 receptor (HER2)-negative
[19,22,24,25,32]. These characteristics also predominate
among tumours arising in patients with germline BRCA1
(breast cancer 1, early onset) mutations [40,41]. Recent stud-
ies have indicated that positive staining for 'basal' markers in
patients with familial breast and/or ovarian tumours is strongly
predictive of carrying a BRCA1 mutation [27,34,41]; however,
there are several lines of evidence to suggest that sporadic
basal-like ductal carcinomas do not harbour BRCA1 somatic
mutations [42].
Despite these morphological, immunohistochemical, and
molecular features, current routine diagnostic practice does
not separately recognise these tumours and management is
the same as for other grade- and stage-matched breast
tumours. Importantly, however, evidence suggests that these
tumours have a metastatic pattern of dissemination and clini-
cal behaviour that are different than comparable ductal carci-
nomas not showing basal marker expression. Tsuda et al. [19]
and Hicks et al. [43] reported a higher incidence of lung and
brain metastases associated with a myoepithelial phenotype,
as defined by CK14, smooth muscle actin, or S100 protein
expression. Furthermore, retrospective, population-based
studies have demonstrated that tumours that express these
basal markers have a more aggressive clinical behaviour when
compared to those with a luminal phenotype and that 'basal'
status may be an independent prognostic factor. In contrast, a
comparative genomic hybridisation (CGH) analysis performed
in our institutions [28] of 86 invasive ductal carcinomas of no
special type (IDC-NST) (50% CK14-positive and stage- and
age-matched), all of which were grade III, did not suggest a
uniformly poor prognosis for the basal-like (CK14-positive)
tumours. Instead, the CGH analysis revealed distinct sub-
groups of basal-like grade III tumours that exhibited a compar-
atively good prognosis with extended clinical follow-up (>10
years), in comparison to the rest of the grade III group, and a
basal-like subgroup with a relatively poor prognosis. In fact, in
contrast to the 'pan-grade' studies, the CK14-positive tumours
appeared to have an overall better outcome than the rest of the
group [28].
To investigate these observations further and explore the
hypothesis that basal-like tumours are entities biologically dis-
tinct from other ductal carcinomas and that they may them-
selves have different subgroups, we assessed a large cohort
Figure 1
Histological appearance of basal tumours and CK14 expression pat erns pat-
terns. (a) Typical histological appearance of a basal breast carcinoma 
(haematoxylin and eosin). (b) CK14 expression: a basal tumour with 
basal keratin expression in almost every tumour cell (diffuse staining 
pattern). (c) Another basal tumour with only a minority of tumour cells 
showing expression (focal staining pattern).Page 2 of 11
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this with long-term survival and pattern of metastatic disease.
Materials and methods
Four hundred and seventy grade III IDC-NST, diagnosed
between 1975 and 1991, were identified from the patient
database at the Hedley Atkins/Imperial Cancer Research
Fund Breast Pathology Laboratory, Guy's Hospital (London,
UK), where all the cases were managed. Tumours had been
graded according to the modified Bloom and Richardson sys-
tem [2] and have been previously published [44]. Immunohis-
tochemistry was performed on a single tumour block for CK14
as detailed previously [28,29]. Briefly, 2 minutes of pressure-
cooking at pH 6.0 was used for antigen retrieval with CK14
clone LL002 (1:50) (BioGenex Inc., San Ramon, CA, USA).
Four hundred and forty-three cases contained tumour on
review.
CK14 expression was assessed independently by two pathol-
ogists (LGF and JSR-F). A tumour was designated as CK14-
positive if it was considered that at least 1% of true invasive
tumour cells expressed the CK marker. From our previous
experience [28,29], and as recently demonstrated by Laakso
et al. [25,26], it has been apparent that whereas in some
tumours virtually every cell expresses the basal marker (CK14,
in this instance), others may show a focal or variable percent-
age of positive cells (Figure 1b,c). We therefore subdivided
the CK14-positive tumours into those showing 'diffuse expres-
sion' (defined as more than 90% of tumour cells positive; Fig-
ure 1b) and those showing 'focal expression' (1% to 90% of
cells positive; Figure 1c). Discrepancies between the observ-
ers were resolved on a multi-headed microscope. For ease of
reading, CK14-positive tumours are referred to henceforth as
'basal' and CK14-negative tumours as 'non-basal' cases. Data
on tumour size, axillary lymph node status, ER, and primary
treatment were available for 98%, 98%, 93%, and 100% of
patients, respectively. Between 1975 and 1991, the method-
ology for ER measurement changed as newer reagents
became available. Initially, ER status was determined by
cytosol ligand-binding assay [45], which was then replaced by
the Abbott enzyme immunoassay (EIA) (Abbott Laboratories,
Abbott Park, IL, USA) [46]. A successful comparative study
was undertaken between the ligand-binding assay and EIA
before transferring to the latter method.
All ER data were recorded on a prospectively acquired and
verified clinicopathological database at the time of assay. Full
clinical follow-up data, including sites of metastatic disease,
were available for all cases.
Statistical analysis
Associations between CK14 immunoreactivity and clinico-
pathological parameters–including tumour size (as defined by
TMN [tumour-node-metastasis] staging, 5th edition), tumour
grade (modified Bloom-Richardson grading) [2], menstrual
status, ER and PR status, presence of axillary lymph node
metastases, local recurrence, and distant metastasis–were
evaluated by Fisher's exact test or χ2 test as appropriate. Mean
age at diagnosis and CK14 positivity were compared using a
t test.
Survival analyses were conducted for overall survival (OS),
disease-free survival (DFS), survival to metastases at specific
sites, and time from first recurrence to death. DFS was defined
as time to any type of recurrence, distant metastasis, or death
from any cause. Survival curves were calculated using the
Kaplan-Meier method. Tests of differences in survival between
groups were performed using the log-rank test and were
expressed as hazard ratios (HRs), which were estimated using
Cox regression. Cox regression analysis was also used to eval-
uate any independent effect of prognostic factors on DFS,
OS, and survival from recurrence. Factors significant at a p
value of less than 0.05 in the survival analysis, together with
CK14 as the factor of principal interest, were included in the
regression analyses. All tests were two-tailed, and 95% confi-
dence intervals are presented where appropriate. All analyses
were carried out using Stata (version 7.0, StataCorp LP,
Texas, USA).
Results
The distribution of clinicopathological features is detailed in
Table 1. Briefly, age at diagnosis ranged from 21 to 85 years
(mean 53.2 years). Fifty-seven percent of tumours had axillary
nodal metastases, and 46% were ER-positive. Fifty-two per-
cent of cases had received no form of adjuvant treatment.
Length of follow-up ranged from 3.2 to 333.5 months, with a
mean follow-up of 116.4 months.
OS and DFS in the whole cohort
Associations of potential prognostic factors with OS, DFS,
and survival from first recurrence are shown in Table 2. As
expected, both OS and recurrence-free survival were inversely
related to the presence of axillary nodal metastases (p <
0.0001) and primary tumour size (p = 0.003). Tumours occur-
ring in women less than 35 years old or more than 65 years old
at diagnosis had poorer OS and DFS than women 35 to 65
years old (p = 0.002 and p = 0.01, respectively). ER- and PR-
negative tumours showed a significantly poorer survival from
first recurrence (HR 2.10, p < 0.0001, and HR 1.51, p =
0.005, respectively). These features are entirely consistent
with the outcomes expected in follow-up of such a group of
grade III breast tumours.
CK14 expression
Of the 443 cases, 88 (20%) showed CK14 expression and
are considered to be 'basal' tumours. They occurred at a
slightly, but significantly, younger age than other grade III
tumours (mean 49.9 years versus 53.9 years, p = 0.0065;
Table 3). They were more likely to be ER- and PR-negative
(odds ratio [OR] 10.9, p < 0.0001, and OR 11.9, p < 0.0001,Page 3 of 11
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(OR 0.44, p = 0.0023). There was no apparent correlation
with tumour size or menopausal status.
Basal phenotype and effect on survival
Basal tumours exhibited a significantly better OS and DFS
than non-basal tumours (HR 0.69, p = 0.02, and HR 0.65, p =
0.005, respectively; Table 2, Figure 2a,b). DFS was similar in
Table 1
Clinicopathological features of the cohort of 470 grade III invasive ductal carcinomas of no special type
Parameter Number
Age in years
Range 21–85 (mean 53.2)
<35 36 (8%)
35–50 142 (32%)
51–65 189 (43%)
>65 76 (17%)
Menopausal status
Premenopausal 175 (40%)
Perimenopausal 64 (15%)
Postmenopausal 195 (45%)
Unknown 9
Tumour size
Range 0.5–10.5 cm (mean 3.4 cm)
p1 27 (6%)
p2 313 (72%)
p3 93 (21%)
Axillary nodes
Positive 251 (57%)
Negative 184 (42%)
Oestrogen receptor
Positive 191 (46%)
Negative 222 (54%)
Not available 30
Surgical management
None 2 (1%)
Mastectomy 318 (72%)
Tumourectomy 123 (28%)
Adjuvant treatment
None 229 (52%)
Tamoxifen/Ovarian oblation 103 (22%)
Chemotherapy and tamoxifen 5 (1%)
Chemotherapy 112 (25%)
Length of follow-up in months 3.2–333.5 (mean 116.4)
Tumour sizes: p1, <2 cm; p2, 2–5 cm; p3, >5 cm.Page 4 of 11
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sis (56% in basal patients, 49% in non-basal patients) but then
diverged (52% versus 38% at 10 years). Similarly, the OS was
almost identical during the first 5 years (60% versus 59%) but
then diverged such that patients with basal tumours survived
significantly longer (survival at 10 years 54% versus 43%).
The difference in survival remained when analyses were
restricted to ER-negative tumours (HR 0.62, p = 0.01, for OS;
HR 0.63, p = 0.01, for DFS). After adjustment for age, tumour
size, and nodal metastases, DFS remained significantly better
in basal cases (HR 0.72, p = 0.05) but the effect on OS was
no longer significant (HR 0.78, p = 0.14; Table 4).
Importantly, considering only breast tumours that relapsed,
expression of basal markers was associated with significantly
poorer prognosis. Survival after first recurrence was signifi-
cantly shorter for basal tumours (HR 1.84, p = 0.001; Figure
2c). Interestingly, most of the recurrences seen in patients with
basal tumours happened in the first 5 years of follow-up.
CK14 expression patterns
Of the 88 basal cases, 24 (27%) fell into the diffuse staining
category and the remaining 64 (73%) showed focal CK14
expression (of these, half exhibited less than 50% tumour cell
expression and the remainder between 50% and 90%). Both
Table 2
Overall survival and disease-free survival data for all tumours
Parameter Overall survival Disease-free survival Survival from recurrence
5-year Hazard ratio (95% CI) p value 5-year Hazard ratio (95% CI) p value Hazard ratio (95% CI) p value
Axillary metastases
No 71% 1.0 <0.0001 65% 1.0 <0.0001 1.0 0.32
Yes 51% 1.83 (1.44–2.33) 41% 1.83 (1.45–2.32) 1.17 (0.86–1.57)
Tumour size
p1 89% 1.0 0.002 70% 1.0 0.0005 1.0 0.26
p2 61% 1.54 (0.92–2.62) 54% 1.49 (0.90–2.48) 1.09 (0.60–1.96)
p3 46% 2.18 (1.25–3.82) 35% 2.20 (1.28–3.79) 1.29 (0.69–2.41)
ER
Positive 64% 1.0 0.68 52% 1.0 0.74 1.0 <0.0001
Negative 52% 1.05 (0.83–1.33) 48% 0.96 (0.76–1.21) 2.1 (1.59–2.79)
PR
Positive 64% 1.0 0.82 49% 1.0 0.55 1.0 0.005
Negative 56% 1.03 (0.80–1.33) 52% 0.93 (0.72–1.19) 1.51 (1.13–2.02)
Age in years
<35 53% 1.0 0.002 39% 1.0 0.01 1.0 0.96
35–50 58% 0.90 (0.57–1.41) 50% 0.99 (0.63–1.55) 0.89 (0.57–1.39)
50–65 64% 0.81 (0.52–1.26) 57% 0.85 (0.55–1.31) 0.89 (0.57–1.38)
>65 54% 1.44 (0.90–2.30) 44% 1.39 (0.87–2.23) 0.89 (0.52–1.50)
CK14
Negative 59% 1.0 0.02 49% 1.0 0.005 1.0 0.001
Positive 60% 0.69 (0.50–0.94) 56% 0.65 (0.48–0.88) 1.84 (1.27–2.65)
CK14 pattern
Negative 59% 1.0 0.005 49% 1.0 0.003 1.0 0.002
Focal 50% 0.92 (0.65–1.28) 48% 0.83 (0.59–1.16) 2.31 (1.54–3.45)
Diffuse 88% 0.31 (0.15–0.63) 79% 0.32 (0.17–0.63) 0.84 (0.35–2.06)
Tumour sizes: p1, <2 cm; p2, 2–5 cm; p3, >5 cm. CI, confidence interval; CK14, cytokeratin 14; ER, oestrogen receptor; PR, progesterone 
receptor.Page 5 of 11
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CK14 staining (p = 0.012 and p = 0.02, respectively). Focally
positive tumours had OS and DFS similar to the non-basal
tumours, whereas the prognosis for diffuse staining was mark-
edly better (Figure 2d,e). Survival from metastasis did not dif-
fer by staining pattern (p = 0.14), but this comparison had very
limited power because there were only nine recurrences in the
diffuse staining group (Figure 2f). Statistical analysis showed
no difference in hormone status, tumour size, axillary nodal sta-
tus, menopausal status, age, or local recurrence between
tumours showing the two different patterns of staining (data
not shown).
Effect of treatment
Because these tumours date from the 1970s, there was wide
variation in treatments. Some patients received tamoxifen and/
or chemotherapy, whereas the majority received no systemic
therapy, as was standard at that time. To investigate whether
the differences in survival seen in the basal tumours may be
related to the introduction of adjuvant therapies, we also
analysed the subset of 229 patients who had received no
adjuvant chemotherapy, hormonal therapy, or ovarian oblation.
In this subset, basal tumours (n = 52, 23%) were still associ-
ated with a significantly improved OS (HR 0.50, p = 0.018)
and DFS (HR 0.48, p = 0.001); however, this effect was not
independent of the nodal status, because basal tumours are
more often node-negative at presentation. These HRs were
greater than for the cohort as a whole (tests for interaction, p
= 0.01 for OS and p = 0.017 for DFS). Among patients
treated with adjuvant hormonal therapy, basal tumours were
associated with a poorer survival (HR 1.76, 95% confidence
interval 0.94 to 3.29). This is likely to reflect the inverse corre-
lation between expression of basal markers and hormone
receptors and the impact of hormone therapy on the survival
of patients with receptor-positive breast cancer.
Basal tumours and sites of metastases
There were clear differences in the development of metas-
tases to specific sites between the basal and non-basal
tumours (Table 5). Basal tumours were significantly less likely
to develop bone (p = 0.01) or liver (p = 0.035) metastases or
have involvement of non-regional lymph nodes (p = 0.008) but
were more likely to develop brain metastases (p = 0.051).
There was no difference in the rate of lung and pleu
ral metastases between the two groups.
Discussion
These data contrast with much of the recently published data
showing entirely poor outcome in basal tumours
[7,8,10,17,33]. Unlike that of previous pan-grade studies, the
aim of this study was to look at the impact of 'basal' phenotype
Table 3
Features of 'basal' versus 'non-basal' tumours
Parameter Basal Non-basal Adjusted odds ratio p value
Oestrogen receptor
Positive 8 (9%) 183 (52%) <0.0001
Negative 72 (81%) 150 (42%) 10.9 (5.08–23.2)
Progesterone receptor
Positive 4 (5%) 122 (33%) <0.0001
Negative 75 (85%) 206 (58%) 11.9 (4.2–33.6)
Axillary nodes
Positive 37 (42%) 214 (60%) 0.0023
Negative 49 (55%) 135 (38%) 0.44 (0.27–0.72)
Tumour size
p1 5 (6%) 22 (6%) 1.0 0.92
p2 66 (75%) 247 (70%) 1.41 (0.50–3.97)
p3 17 (19%) 76 (21%) 1.19 (0.38–3.7)
Menopausal status
Premenopausal 42 (47%) 133 (37%) 1.0
Perimenopausal 15 (17%) 49 (14%) 1.91 (0.71–5.19)
Postmenopausal 33 (38%) 164 (46%) 1.31 (3.80)
Mean age in years 49.9 (SE 1.30) 53.9 (SE 0.65) 0.0065
Tumour sizes: p1, <2 cm; p2, 2–5 cm; p3, >5 cm. SE, standard error.Page 6 of 11
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a subgroup with a traditionally poor prognosis. We have spe-
cifically chosen a cohort of cases diagnosed historically as
grade III ductal carcinomas, not including any special subtypes
such as metaplastic breast carcinoma or medullary carcinoma,
because this is the group of tumours in which the majority of
basal cases seem to arise [5].
Terminology and definitions surrounding the concept of basal
tumours are controversial, and a plethora of different markers
and definitions have been employed to identify cases in clinical
studies. Nielsen and colleagues [22] have proposed a defini-
tion based on ER, HER2, CK5/6, and EGFR (epidermal
growth factor receptor) expression; however, even this defini-
tion does not show a perfect correlation with microarray data.
Indeed, there is no accepted gold standard on which to
Figure 2
Long term survival in basal versus non-basal tumours. (a-c) Kaplan-Meier survival plots for basal (dashed line) versus non-basal (solid line) tumours. 
(a) Overall survival, (b) disease-free survival, and (c) survival from metastasis. (d-f) Kaplan-Meier survival plots for diffuse basal (short dashes) versus 
focal basal (long dashes) versus non-basal (solid line) tumours. (d) Overall survival, (e) disease-free survival, and (f) survival from metastasis.Page 7 of 11
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80% of tumours classified as HER2 by cDNA microarrays
overexpressed HER2 at the immunohistochemical level).
Given that there is currently no consensus terminology or inter-
nationally accepted definition (morphological or immunophe-
notypic) for basal-like tumours, we have employed CK14 alone
to identify basal tumours in the present study. Our reasons for
choosing a single marker are pragmatic: (a) limited material
from this unique cohort of patients was available, and (b)
CK14 is a marker that we have had considerable experience
with and forms the basis for previous studies in the laboratory
[28,29,36]. Furthermore, it has been demonstrated that CK14
expression correlates strongly with other 'basal' markers and
that it identifies basal tumour proportions similar to those of
other investigators (for example, CK5/6, CK17, and P-cad-
herin) [21-26,32,33,35].
Our results have highlighted several important features of
basal tumours as identified by CK14 expression. Relative to
other grade III tumours, they are much more likely to be ER-
negative and less likely to be axillary node-positive. They show
lower rates of metastasis to the bone and liver but a higher rate
of brain metastasis. Over the first 5 years after diagnosis, the
relapse-free survival and OS appear to be similar to other
grade III tumours, but their subsequent prognosis is much bet-
ter. Given that in this study we compared grade III tumours
only and that basal-like phenotype and 3+ expression of HER2
are more prevalent in this group but are inversely correlated
[9,22,39,47], it is likely that the non-basal-like tumours include
a high prevalence of HER2-amplified tumours [47], which are
reported to have an aggressive clinical behaviour. Further
studies to directly compare the contribution of basal-like and
HER2 phenotypes to survival of patients with grade III ductal
carcinomas are warranted but are outside the remit of this
study. The pattern of recurrence in basal tumours, with almost
all recurrences occurring in the first 5 years, also differs from
non-basal tumours, in which late relapse is widely recognised.
Previous studies, many of which have a shorter median follow-
up than that of our cohort of patients, have indicated that basal
tumours usually have a very poor prognosis when compared to
a mixture of grades I, II, and III basal keratin-negative breast
tumours [7,8,10,17,32,33]. These observations are not nec-
essarily inconsistent with this study, because our study does
indicate a poor survival for patients with basal tumours for the
first 5 years of follow-up.
The findings suggest the existence of two subgroups of basal
carcinomas: one exhibiting early relapse and aggressive clini-
cal course and a separate group that despite the traditionally
poor prognostic indicators do not relapse. This would be con-
sistent with the findings of our previous CGH analysis [28],
which was carried out on a subset of the tumours examined in
the present study and was able to split the basal tumours into
two groups based on both their molecular genetic alterations
and prognosis.
We found that traditional clinicopathological parameters could
not discriminate between 'good' and 'bad' basal tumours. In
addition, we found that none of the specific morphological fea-
tures associated with the basal phenotype [36], such as cen-
tral scar, high mitotic rates, pushing growth pattern, or
necrosis, occurred with any significant difference between
good and bad basal cases. However, the pattern of CK14
expression shows clear differences in prognosis. Those with a
diffuse (>90%; Figure 1b) staining pattern seem to fall largely
into the good-prognosis group of tumours. A similar subclassi-
fication of basal tumours according to the expression of basal
keratins into basal and basoluminal subtypes also suggested
that tumours with a pure basal phenotype had a better prog-
nosis [26].
Table 4
Cox regression analysis
Overall survival Disease-free survival
Prognostic factor Level Hazard ratio (95% CI) p value Hazard ratio (95% CI) p value
Basal CK14-
positive
0.78 (0.56–1.08) 0.14 0.72 (0.52–0.99) 0.05
Age group in years <35 1.0 0.0005 1.0 0.005
35–49 0.86 (0.54–1.37) 0.96 (0.60–1.52)
50–64 0.77 (0.49–1.22) 0.80 (0.51–1.26)
65+ 1.50 (0.91–2.46) 1.43 (0.87–2.36)
Tumour size p1 1.0 0.052 1.0 0.042
p2 1.45 (0.84–2.48) 1.40 (0.83–2.36)
p3 1.87 (1.06–3.31) 1.92 (1.10–3.33)
Lymph node metastasis Positive 1.83 (1.42–2.35) <0.0001 1.81 (1.42–2.32) <0.0001
Tumour sizes: p1, <2 cm; p2, 2–5 cm; p3, >5 cm. CI, confidence interval; CK14, cytokeratin 14.Page 8 of 11
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mutation carriers are of basal type [27,34,41], our observa-
tions are also relevant to the prognosis in these women. Stud-
ies of prognosis in BRCA1 germline mutation carriers have
been inconsistent; studies based on carriers identified through
clinical testing in high-risk families have shown a relatively
good prognosis, whereas studies based on testing of popula-
tion series have shown a poor prognosis [48]. This apparent
inconsistency could be explained by our results because
cases undergoing clinical testing will tend to be identified
some time after diagnosis when subsequent prognosis is
good.
These concepts have important implications for patient man-
agement. This study confirms that there is a group of aggres-
sive basal tumours that are currently not identified in routine
diagnostic practice but that show a biological behaviour differ-
ent from other grade III IDC-NST. They relapse early with short
subsequent survival and notably carry a higher risk of brain
metastases [19,43]. These tumours may need different (for
example, platinum-based) [49] chemotherapy regimens or
more aggressive therapeutic regimens and may need to be
specifically identified in laboratory research designed to iden-
tify new therapeutic targets.
Table 5
Number and sites of metastases and time taken for metastases to develop in 'basal' versus 'non-basal' tumours
Site of metastasis Number 5-year proportion free of 
metastases
Hazard ratio p value
Basal Non-basal Basal Non-basal (95% CI)
All sites
No 51 169 59% 55% 0.65 (0.48–0.88) 0.005
Yes 37 186
Bone
No 74 245 85% 73% 0.49 (0.28–0.86) 0.01
Yes 14 109
Liver
No 76 265 86% 77% 0.53 (0.29–0.97) 0.035
Yes 12 89
Brain
No 75 327 85% 93% 1.92 (0.27–1.01) 0.051
Yes 13 27
Lung/pleura
No 65 261 73% 77% 0.92 (0.58–1.46) 0.72
Yes 23 93
Skin
No 79 316 87% 90% 0.94 (0.45–1.95) 0.87
Yes 9 38
Pericardial/mediastinum
No 84 342 94% 97% 1.23 (0.39–3.83) 0.72
Yes 4 12
Nodes (non-regional)
No 83 293 93% 84% 0.31 (0.13–0.78) 0.008
Yes 5 61
CI, confidence interval.Page 9 of 11
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Breast Cancer Research    Vol 9 No 1    Fulford et al.It is also clear from these results that expression of basal mark-
ers alone cannot be used to indicate a tumour with poor prog-
nosis. Indeed, it may be that some of the basal tumours with a
better prognosis will require much less aggressive therapy and
follow-up and that patients can be reassured of their long-term
outlook despite being diagnosed with a grade III cancer.
Conclusion
This study shows that identifying basal tumours as a distinct
group has real clinical relevance. They are relatively common,
occurring in approximately 20% of grade III IDC-NST and
approximately 10% of breast tumours overall. In the UK, with
approximately 50,000 new breast tumours diagnosed each
year, we may be missing some 5,000 basal tumours that carry
distinct, but mixed, prognostic implications and that may
respond differently to conventional chemotherapy regimens.
The aim now is finding ways to further identify, characterise,
and define 'good' and 'bad' basal tumours and to tailor man-
agement appropriately. Furthermore, these tumours may
express distinct targets for novel therapeutic regimens, and
research programmes should bear this in mind. Clinicopatho-
logical, therapeutic, and molecular genetic approaches will
almost certainly all play a part in this task.
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